Autopsy report · NCT02723006

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

“Business decision: Protocol efficacy futility met”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 1 year 11 months before it stopped.
• 22 participants enrolled.
• Results were posted on the registry 2 years 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Millennium Pharmaceuticals, Inc.

Sponsor type

Industry

Conditions

Melanoma

Interventions

TAK-580; TAK-202; vedolizumab; nivolumab; ipilimumab

Participants

22

Sites

14

Countries

United States

Trials that died the same way

• Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus ORT for Dehydrated Children in the Emergency Department (ED)
  “Strategic business decision (not related to safety or efficacy concerns)” (71% match in meaning)
• A Study of RBI-4000 in Healthy Participants
  “Strategic business decision (not related to safety, efficacy, or quality)” (70% match in meaning)
• A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children
  “Business decision” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.